TSE:3407Chemicals
Does New NefIgArd Phase 3 IgAN Data Shift The Bull Case For Asahi Kasei (TSE:3407)?
Calliditas Therapeutics AB, an Asahi Kasei company, has recently announced that new Phase 3 NefIgArd study data in primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology in Yokohama, Japan, including secondary, biomarker, and mechanistic analyses of its gut-targeted therapy Nefecon.
This extensive dataset, spanning seven scientific posters and a dedicated symposium on the evolving IgAN treatment paradigm, underscores Asahi Kasei’s growing...